SEPCELL consortium gathers six partners from four European countries (Spain, France, Netherlands and Belgium). The consortium is made up by a combination of research institutes, medical entities and biotech oriented SMEs, congregating thus the necessary competence and critical mass in terms of expertise and resources that ensures the achievement of the project goals.
GENERAL INFORMATION ABOUT THE CONSORTIUM
Centre Hospitalier Universitaire de Limoges, France
The Centre Hospitalier Universitaire de Limoges (CHUL) was created in 1976 with three public service missions: patient care, teaching and research and innovation. CHUL is composed by 5 different hospitals with more than 7,000 professionals and an Inserm certified Centre of Clinical Investigation (CIC-P).
CHUL provides the expertise and the skills of clinical research in the field of emergency trials and more specifically within sepsis, led by Dr. Bruno François, medical coordinator of the CIC-P. CHUL clinical research centre is one of the leading academic platforms in the field of sepsis in France and the European Union, capable of performing multicentre studies with specialization in the development of Phase II studies in critically ill patients with sepsis, ventilator-associated pneumonia (VAP) or acute respiratory distress sydrome (ARDS), among others.
The principal investigator within the project, Dr. Bruno François, is intensivist, head of the CIC-P and co-head of the medical-surgical Intensive Care Unit at Limoges University Hospital. He is coordinator of the national network of Inserm research centers for sepsis.
Servicio Madrileño de Salud-Fundación para la Investigación Biomédica del Hospital Clínico San Carlos, Spain
The Hospital Clínico San Carlos has been providing health care since 1787 and has among its objectives the improvement of patient´s care, providing education and training to professionals, and developing research programs in the medical field. Rebuilt in the 60s, the hospital has been changing in order to be adapted to the demands of Madrid society, being a reference to national and international level by the level of its facilities and its professionals. The hospital has more than 5,000 professionals and is considered the main center of reference in the training of health professionals from the Complutense University of Madrid.
The Intensive Medicine Unit of Hospital Clínico San Carlos, head by Dr. Miguel Sánchez García (principal investigator within the project) is one of the oldest ICU in Spain being the reference hospital in the Community of Madrid with a strong focus in research in the clinical practice. The service is actively involved in funded multicenter clinical trials in areas of nutrition, infection, preventing infection and sepsis.
Academic Medical Center, Netherlands
The Academic Medical Centre (AMC) in Amsterdam is one of the most prominent medical centres in the Netherlands, recently accredited by the Joint Commission International (JCI). The AMC has over 7,000 employees and 1,000 hospital beds.
The AMC has a long tradition of medical science and translational research and each year approximately 160 Ph.Ds are awarded. The AMC complex houses the University Hospital, the medical faculty of the University of Amsterdam, the Netherlands Institute for Neuroscience, the Amsterdam Institute for Global Health and Development, the medical department of the Royal Tropical Institute and a number of (AMC ‘spin off’) biotech companies.
One of the themes the AMC aspires to excel in is Infectious Diseases & Immunity. Within the AMC, the Department of Internal Medicine, Division of Infectious Diseases, provides clinical care to patients with infectious diseases. The Centre for Infection and Immunity Amsterdam (CINIMA) houses the main laboratories within the University of Amsterdam and AMC involved in research in the field of Infectious Diseases and Immunity. The Centre for Experimental and Molecular Medicine (CEMM), a former Marie Curie Training site, is the largest laboratory of CINIMA and houses over 100 members of personnel, including staff members, post-doctoral researchers, PhD students and technicians.
The principal investigator within the project, Dr. Tom van der Poll, is professor of Medicine at AMC. He is the Head of the Center of Experimental and Molecular Medicine and is the Chair of the Division of Infectious Diseases in this institution. He is board certified in Internal Medicine and Infectious Diseases and a Member of the Dutch Health Council, the official advisory board of the Dutch government and parliament. His research focuses on the innate immune and procoagulant response during sepsis. This research seeks to combine observational studies in patients with preclinical and fundamental studies in healthy volunteers and experimental animals.
Cliniques Universitaires Saint-Luc, Catholic University of Leuven, Belgium
Cliniques Universitaires Saint-Luc is the academic hospital of the Catholic University of Leuven (UCL) and was created in 1976.
The 3 main missions are: provide patient care, provide education and support research. The Cliniques Universitaires Saint-Luc count approximately one thousand beds and offer a wide range of treatments. Thanks to their highly specialized teams and continuous investments in state of the art medical equipment, Saint-Luc can treat the most complex pathologies. As an academic hospital, Cliniques Universitaires Saint-Luc believes strongly in integrating clinical research into high-level medicine for the benefit of patients.
Cliniques Universitaires Saint-Luc has a world recognized experience in the field of sepsis and is specialized in the development of clinical trials in the management, early diagnosis and treatment of sepsis.
The principal investigator within the project, Professor Pierre-François Laterre, is Chief of the Intensive Care Service at Saint-Luc University Hospital. His research interests center on the management of severe sepsis and septic shock, ARDS but also severe pancreatitis and liver failure. He is a member of many national and international societies including the Belgian Intensive Care Society and the European Intensive Care Society, among others. He is a member of the scientific commission of the French Society of Critical Care Medicine.
TiGenix, NV-TiGenix SAU. Leuven, Belgium & Madrid, Spain
TiGenix (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells.
Two products from the adipose-derived stem cell technology platform are currently in clinical development. Cx601 finished a Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients and is currently in the process of marketing authorization application. Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis.
On July 4, 2016, TGenix entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States.
TiGenix NV is based in Leuven, Belgium, and TiGenix SAU leads the operations in Madrid, Spain.